Physician profile
Vipulkumar Devani
NPI 1619577723
$13,885.13
in general payments reported to CMS, 2019-2025
27 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,470 · 2022: $2,673 · 2023: $2,890 · 2024: $3,516 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,583 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,583.05 |
| Education | $158.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,065.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,774.38 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,463.92 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,268.09 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,147.03 | 2021-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Lundbeck LLC | $834.84 | 2021-2025 | Rexulti |
| Corium, LLC | $729.33 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $667.75 | 2022-2025 | Auvelity |
| Alkermes, INC. | $650.34 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $611.33 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $590.78 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $404.32 | 2022-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $354.17 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $349.21 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $232.63 | 2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $159.18 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Indivior INC. | $108.63 | 2022-2024 | Perseris |
| Tris Pharma INC | $96.51 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Sage Therapeutics, LLC | $86.25 | 2024-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $86.25 | 2022-2024 | |
| Almatica Pharma LLC | $51.08 | 2024-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $41.65 | 2022 | |
| Collegium Pharmaceutical, INC. | $30.91 | 2025 | Jornay Pm |
| Tempus Ai, INC | $24.68 | 2025 | Tempus Pixel |
| Luye Pharma (USA) Ltd. | $21.88 | 2025 | Erzofri Extended-Release |
| Owp Pharmaceuticals, INC. | $21.47 | 2021 | |
| Eisai INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipulkumar Devani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.